Comment on: Extracorporeal hemoadsorption in critically ill COVID‑19 patients on VV ECMO: the CytoSorb therapy in COVID‑19 (CTC) registry

[...]all findings from this registry study should primarily be used to generate hypotheses for future studies and not be used prematurely to inform treatment decisions and standards. [...]the application of CytoSorb is not well described within this study. [...]the interesting results presented from...

Full description

Saved in:

Bibliographic Details
Published in:	Critical care (London, England) Vol. 27; no. 1; p. 297
Main Authors:	Supady, A, Staudacher, D L, Wengenmayer, T
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 24-07-2023 BioMed Central BMC
Subjects:	Correspondence COVID-19 Critical care Critical Illness Cytokines Extracorporeal Membrane Oxygenation Humans Mortality Patients Registries Ventilation Ventilators
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	[...]all findings from this registry study should primarily be used to generate hypotheses for future studies and not be used prematurely to inform treatment decisions and standards. [...]the application of CytoSorb is not well described within this study. [...]the interesting results presented from the CTC registry lack relevant information to support the conclusion of a favorable treatment effect of hemoadsorption in COVID-19 patients on ECMO and should therefore be interpreted very cautiously.
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 ObjectType-Commentary-2
ISSN:	1364-8535 1466-609X 1364-8535 1366-609X
DOI:	10.1186/s13054-023-04578-4